Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,662.67
(
-0.80%
)
US TECH 100
23,989.60
(
-0.59%
)
Dow Jones
46,453.32
(
-1.15%
)
Brent Oil
104.98
(
4.30%
)
Bitcoin
71,676.44
(
-3.06%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 162890

Tuesday, 07/09/2013 11:26:04 AM

Tuesday, July 09, 2013 11:26:04 AM

Post# of 257253
ENTA—A phase-1b/2a monotherapy trial of EDP-239 has been started by NVS, which is the first public sign that NVS really cares about the EDP-239 program. (Source: ENTA’s JMP webcast today.) My ENTA valuation model ascribes zero value for EDP-239, so anything that does happen is all upside.

Please see #msg-89280314 for a summary of the potential milestones for ENTA from the EDP-239 program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now